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Edited by Ivan SadowskiAbstract Resveratrol, a polyphenolic compound found in the
skin of red fruits, exhibits anti-inﬂammatory, anti-oxidative,
and anti-proliferative characteristics. Transforming growth fac-
tor-b (TGF-b) is a pleiotropic cytokine that also displays such
properties. We therefore hypothesized that there might be a func-
tional link between resveratrol and TGF-b. This study reports
that resveratrol increased transcription of the TGF-b2 gene, en-
hanced the production of TGF-b2 protein, and activated Smad
signaling in an autocrine manner in A549 human lung epithelial
cell line. Thus, some of the beneﬁcial eﬀects of resveratrol on
human health might be mediated, in part, through its eﬀects on
TGF-b expression and signaling.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Resveratrol (trans-3,4 0,5-trihydroxystilbene) is a polypheno-
lic compound that is abundant in grapes and red wine [1,2].
Resveratrol has been reported to exhibit anti-inﬂammatory,
anti-oxidative, and anti-carcinogenic (anti-proliferative) prop-
erties by multiple molecular mechanisms [1–4], including act-
ing as a free radical scavenger. In addition, the structure of
resveratrol is similar to the structure of estradiol, and resvera-
trol acts as an estrogen agonist or antagonist depending on
experimental conditions [5,6].
Transforming growth factor-b (TGF-b) is a multifunctional
cytokine that is involved in a variety of cellular activities (pro-
liferation, diﬀerentiation, extracelluar matrix regulation, and
survival) [7]. TGF-b is secreted as inactive (latent) precursors
into the extracellular space and is activated by several mecha-
nisms which are not fully understood [8]. TGF-b signals
through two serine/threonine kinase receptors (termed type I
and type II) and the Smad family of proteins [9]. The type I
receptor is activated by the type II receptor upon ligand bind-
ing and induces the phosphorylation of Smad2 and Smad3,*Corresponding author. Address: Department of Immunology, Fac-
ulty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo,
Yamanashi 409-3898, Japan. Fax: +81 55 273 9542.
E-mail address: anakao@yamanashi.ac.jp (A. Nakao).
0014-5793/$34.00  2008 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2008.01.024which in turn form complexes with Smad4. The resulting Smad
complex then moves into the nucleus, binds to the Smad-bind-
ing elements located in the promoter region of the target genes,
and regulates their transcription.
Through its pleiotropic eﬀects on many types of cells,
TGF-b has been shown to exhibit anti-inﬂammatory, anti-
oxidative, and anti-carcinogenic (anti-proliferative) eﬀects
[8,10–12]. For example, TGF-b1 null mice die of massive
inﬂammatory lesions in many organs immediately after birth
[10] and TGF-b displays a strong anti-mitogenic activity in
epithelial and hematopoietic cells [12]. Because these proper-
ties of TGF-b overlap with those of resveratrol, we hypoth-
esized that TGF-b might be involved in some of the
beneﬁcial eﬀects that have been ascribed to resveratrol. To
test the hypothesis, this study investigated whether resvera-
trol, at concentrations that can be attained by red wine in-
take (1–10 lM) [1], aﬀects TGF-b expression and signaling
in several human cell lines.2. Materials and methods
2.1. Reagents
Resveratrol and HTS466284, a selective small molecule inhibitor of
TGF-b type I receptor kinase [13], were purchased from Calbiochem
(San Diego, CA). 4-Hydroxytamoxifen (Tamoxifen), ICI182780 (Flu-
vestrant), and 17-b estradiol were purchased from Sigma–Aldrich
(St. Louis, MS). Recombinant human TGF-b1 and anti-human
TGF-b type II receptor antibody were purchased from R&D Inc.
(Minneapolis, MN).
2.2. Cell culture
The human alveolar carcinoma cell line A549 [14] (RIKEN Cell
Bank, Ibaragi, Japan) was maintained in DMEM medium (Invitro-
gen/Gibco, Carlsbad, CA) containing 10% FCS and antibiotics.
2.3. Reporter plasmid
(CAGA)12-luciferase reporter plasmid, which is exclusively activated
by TGF-b-induced complex between Smad3 and Smad4, has been
described previously [15]. TGF-b-inducible plasminogen activator
inhibitor-1 (PAI-1) promoter-luciferase reporter plasmid has been pre-
viously described [15]. Human TGF-b2 promoter-luciferase reporter
plasmid was generated by inserting DNA fragments of the promoter
regions of the human TGF-b2 gene (639 to 69 from the transcrip-
tional initiation site) into the pGL3-basic vector (Promega, Madison,
WI) as previously described [16].
2.4. Transcriptional reporter assay
Cells were seeded at 3 · 104/well in 24-well plates. We then transfec-
ted the cells with 200 ng of each reporter construct and 5 ng of pRL-
TK Renilla luciferase vector (Promega, Madison, WI), an internalblished by Elsevier B.V. All rights reserved.
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
TG
F-
β2
-lu
c
DMSO 3       10   
Resveratrol (μM)
*
*
10
8
6
4
2
0
12
700
600
500
400
300
200
100
0
800
(–)  DMSO   10 TGF-β1
Resveratrol (μM) 
*
–Tamoxifen
+Tamoxifen
*
To
ta
l T
G
F-
β2
 p
ro
du
ct
io
n
(pg
/m
l)
–Tamoxifen
TGF-β1
3
F. Suenaga et al. / FEBS Letters 582 (2008) 586–590 587control for transfection eﬃciency, using FuGENE 6 transfection re-
agent (Roche Diagnostics, Basel, Switzerland). After 12 h, the cells
were stimulated with 0.1% DMSO, 3 or 10 lM resveratrol, 10 pM
estradiol, or 10 ng/ml TGF-b1 with or without 10 nM 4-hydroxytam-
oxifen or 1 lM ICI182780. Ninety-six hours after the stimulation,
the ﬁreﬂy and Renilla luciferase activities were measured as previously
described [16].
2.5. TGF-b2 ELISA
The amounts of TGF-b2 in the culture supernatants were deter-
mined using the human TGF-b2 ELISA kit (R&D, Minneapolis,
MN) according to the manufacturers instructions. For determination
of the total TGF-b concentrations, the samples were activated by an
acidiﬁcation procedure prior to the ELISA assay.
2.6. Quantitative real-time PCR
Quantitative PCR analysis using cDNAs from the A549 cell line
specimens was performed using the AB7500 real-time PCR system
(Applied Biosystems, Foster City, CA), according to the manufac-
turers instructions using primers and probes for human TGF-b2 and
b-actin (Applied Biosystems).
2.7. Western blotting
Whole cell extracts (10 lg) were subjected to immunoblotting with
anti-phosphorylated Smad3 antibody or Smad2/3 antibody (Cell Sig-
naling Technology Inc., Danvers, MA) as previously described [17].
2.8. Data analysis
The data are summarized as the means ± S.D. The unpaired Stu-
dents t-test was used for the statistical analysis of the results.
P < 0.05 was considered to be signiﬁcant. Representative results of
three independent experiments are shown.700
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Fig. 1. Resveratrol upregulates TGF-b2 expression in A549 human
lung epithelial cells via estrogen receptors. (A) A549 cells were
transfected with TGF-b2 promoter-reporter plasmid and stimulated
with the indicated doses of resveratrol, control DMSO, or 10 ng/ml
TGF-b1. Ninety-six hours after the stimulation, the luciferase activity
was measured. The relative activity was calculated by assigning the
relative luciferase activity of DMSO a value of 1. (B) and (C) A549
cells were cultured in a medium containing 10% FCS in the presence or
absence of the indicated doses of resveratrol, control DMSO, or 10 ng/
ml TGF-b1 with or without 10 nM 4-hydroxytamoxifen (Tamoxifen)
(B) or in the presence or absence of 10 pM estradiol or control DMSO
with or without 10 nM 4-hydroxytamoxifen (Tamoxifen) (C) for 96 h
and the concentrations of total TGF-b2 in the supernatants were
estimated by ELISA. Each experiment was conducted in triplicate for
each sample, and the results are expressed as means ± S.D. *P < 0.05.3. Results and discussion
3.1. Resveratrol increases TGF-b2 expression in A549 human
lung epithelial cells via estrogen receptors
To investigate whether resveratrol aﬀects TGF-b expression,
we initially examined its eﬀects on the TGF-b2 promoter-lucif-
erase reporter construct that contains the promoter regions of
the human TGF-b2 gene in several human epithelial cell lines
including HaCaT (keratinocyte cell line), PANC-1 (pancreatic
cancer cell line), HeLa (uterus cancer cell line), ZR75-1 (breast
cancer cell line), and A549 (lung epithelial cell line). Among
the cell lines tested, both 3 and 10 lM resveratrol caused a sig-
niﬁcant increase in the reporter activity only in A549 human
lung epithelial cell line (Fig. 1A and data not shown). In addi-
tion, the ELISA assay revealed that the amounts of total TGF-
b2, but not TGF-b1 and -b3, protein increased after stimula-
tion with 3 and 10 lM resveratrol in A549 cells (Fig. 1B and
data not shown). We conﬁrmed that both 10 and 30 lM con-
centrations of resveratrol did not aﬀect the cell viability in
A549 cells (data not shown).
Resveratrol is structurally similar to estradiol and acts as an
estrogen agonist or antagonist depending on the experimental
conditions [5,6]. Although the presence of estrogen receptors in
human lung tumors has been controversial for many years,
Stabile et al. recently demonstrated that some forms of estro-
gen receptor a and b are indeed present in normal lung cells
as well as in lung cancer cells, including A549 cells [18]. To
determine whether the resveratrol-induced TGF-b2 expression
in A549 cells was via estrogen receptors, the eﬀects of the estro-
gen receptor antagonist 4-hydroxytamoxifen on the resvera-
trol-induced TGF-b2 expression were examined in A549
cells. An ELISA assay showed that 4-hydroxytamoxifen(Tamoxifen) signiﬁcantly inhibited the resveratrol-induced in-
crease of TGF-b2 protein in A549 cells (Fig. 1B). We also dis-
covered that 10 pM estradiol stimulated the production of
TGF-b2 protein in A549 cells, and this production was
blocked with 4-hydroxytamoxifen (Fig. 1C). These results sug-
gest that resveratrol, as an estrogen agonist, induced the for-
mation of TGF-b2 protein through estrogen receptors in
A549 cells.
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588 F. Suenaga et al. / FEBS Letters 582 (2008) 586–5903.2. Resveratrol increases TGF-b/Smad-dependent promoter
activity in A549 human lung epithelial cells in an autocrine
manner
Because resveratrol increased TGF-b2 expression in A549
cells (Fig. 1), we investigated whether the resveratrol-induced
TGF-b2 activates TGF-b signaling in A549 cells in an auto-
crine manner. The TGF-b-inducible (CAGA)12-luciferase re-R
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ig. 2. Resveratrol increases TGF-b/Smad-dependent promoter activ-
ty in A549 human lung epithelial cells via endogenous TGF-b. (A) and
B) A549 cells were transfected with (CAGA)12-luciferase reporter
lasmid (A) or with PAI-1 promoter-luciferase reporter plasmid (B)
nd stimulated with 3 or 10 lM of resveratrol or control DMSO with
r without 10 lMHTS466284 or 10 lg/ml anti-TGF-b type II receptor
ntibody (aTGF-b RII). Ninety-six hours after the stimulation, the
uciferase activity was measured. (C) A549 cells were transfected with
CAGA)12-luciferase reporter plasmid and stimulated with 3 or 10 lM
f resveratrol or control DMSO with or without 10 nM 4-hydroxy-
amoxifen (Tamoxifen), 1 lM ICI182780, or 10 ng/ml TGF-b1.
inety-six hours after the stimulation, the luciferase activity was
easured. Relative activity was calculated by assigning a value of 1 to
he relative luciferase activity of DMSO control. Each experiment was
onducted in triplicate for each sample and the results are expressed as
eans ± S.D. *P < 0.05.porter construct and the plasminogen activator inhibitor-1
(PAI-1) promoter-luciferase reporter constructs were transfec-
ted into A549 cells and then the transfected cells were stimu-
lated with resveratrol. Notably, 10 lM resveratrol
signiﬁcantly increased the luciferase activities of the
(CAGA)12-luciferase reporter construct and both 3 and
10 lM resveratrol signiﬁcantly increased the PAI-1 pro-
moter-luciferase reporter construct in A549 cells (Fig. 2A
and B). In comparison, TGF-b1 caused an almost 100-fold in-
crease in the (CAGA)12 promoter activity in A549 cells
(Fig. 2C).
To determine whether the TGF-b2 that is induced by res-
veratrol contributes to the increased (CAGA)12- and PAI-1
promoter-luciferase reporter activities in A549 cells in an
autocrine manner, we then examined the eﬀects of the
anti-TGF-b type II receptor antibody and HTS466284, a
TGF-b type I receptor kinase inhibitor [13], on the resvera-
trol-induced increase of the (CAGA)12- and PAI-1 promoter-
luciferase reporter activity. Both the anti-TGF-b type II
receptor antibody and HTS466284 signiﬁcantly reduced the
increase in (CAGA)12- and PAI-1 promoter-luciferase repor-
ter activity mediated by resveratrol in A549 cells (Fig. 2A
and B). In addition, 4-hydroxytamoxifen (Tamoxifen) and
ICI182780, another selective inhibitor of estrogen receptor,
inhibited resveratrol-induced increase of the (CAGA)12-pro-
moter-luciferase reporter activity (Fig. 2C). These results
suggested that resveratrol increases TGF-b/Smad-dependent
promoter activity in A549 human lung epithelial cells via
the induction of endogenous TGF-b and also via the estro-
gen receptor.3.3. Kinetics of TGF-b2 mRNA expression and Smad3
phosphorylation following the stimulation with resveratrol in
A549 human lung epithelial cell line
The above results suggest that resveratrol initially up-regu-
lates TGF-b2 expression via estrogen receptor and then the
endogenously produced TGF-b2 activated Smad signaling in
an autocrine manner in A549 cells. To conﬁrm that resveratrol
indeed up-regulates TGF-b2 and then activates TGF-b/Smad
signaling in A549 cells, the kinetics of TGF-b2 mRNA in
A549 cells following the stimulation with resveratrol were
examined because TGF-b is a strong inducer of transcription
of TGF-b gene itself [19] (Fig. 3A). The TGF-b2 mRNA
expression was initially up-regulated at 15 min after the stimu-
lation with resveratrol, following the gradual decrease. Start-
ing at 4 h, the TGF-b2 mRNA expression again increased in
A549 cells with its peak at 72 h after the stimulation. In con-
trast, the stimulation with TGF-b1 rapidly (at 15 min) in-
creased TGF-b2 mRNA expression without any further
increase (Fig. 3A and data not shown). These results suggest
that resveratrol indeed up-regulates TGF-b2 and then acti-
vates TGF-b/Smad signaling in A549 cells, resulting in the sec-
ond wave of increase in TGF-b2 mRNA levels.
Consistent with the real-time PCR data, resveratrol-induced
phosphorylation of Smad3 was observed at 4 h after the stim-
ulation, whereas TGF-b-induced phosphorylation of Smad3
was rapidly observed at 15 min after the stimulation in A549
cells (Fig. 3B). The resveratrol-induced phosphorylation of
Smad3 was inhibited by HTS466284, 4-hydroxytamoxifen
(Tamoxifen) and ICI182780 in A549 cells (Fig. 3C). These
ﬁndings suggest that resveratrol-induced phosphorylation of
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Fig. 3. Kinetic of TGF-b2 mRNA expression and Smad3 phosphor-
ylation following stimulation with resveratrol in A549 human lung
epithelial cells. (A) A549 cells cultured in DMEM containing 0.1%
FCS were stimulated with 10 lM resveratrol or 10 ng/ml TGF-b1 for
the indicated times. RNA was then extracted and real-time PCR for
TGF-b2 and b-actin was performed. The ratio of each gene to that of
b-actin was calculated, and the value of 1 was assigned to A549 cells at
0 min. (B) and (C) A549 cells cultured in DMEM containing 0.1% FCS
were stimulated with 10 lM resveratrol or 10 ng/ml TGF-b1 with or
without 10 lM HTS466284, 10 nM 4-hydroxytamoxifen (Tamoxifen),
or 1 lM ICI182780 for the indicated times. Western blot analysis with
speciﬁc antibodies against human phosphorylated Smad3 and Smad2/3
was then performed.
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served at the later time points when endogenous TGF-b2
mRNA was induced, also supporting the earlier results.
Resveratrol-induced TGF-b2 expression and TGF-b/Smad-
dependent promoter activation were relatively low in compar-
ison to those induced by TGF-b1 in A549 cells (Figs. 1 and 2).
Since TGF-b2 is produced by a latent form, the weak eﬀect of
resveratrol may be due to requirement of an activation step for
latent TGF-b2, compared to the addition of exogenous ligand.Resveratrol can be consumed daily through wine or fruit, and
the weak activity of resveratrol on TGF-b expression and sig-
naling might ensure the safety of resveratrol consumption and
prevent the unfavorable eﬀects of TGF-b such as ﬁbrosis. We
speculate that long-term intake of resveratrol by wine or fruit
may cause a very slight change in TGF-b expression and sig-
naling activity, resulting in beneﬁcial eﬀects on human health.
Lu et al. reported that >5 lM resveratrol-induced TGF-b2
mRNA expression in an estrogen receptor-positive human
breast cancer cell line (MCF-7) [20].
Our ﬁndings have provided a novel insight into the mecha-
nism underlying their observation and extended their study
in that (1) the eﬀects of resveratrol on TGF-b2 expression
was via estrogen receptors and was relatively weak in compar-
ison to the eﬀects of other stimulations (TGF-b and estradiol),
(2) resveratrol activated TGF-b/Smad signaling through TGF-
b in an autocrine manner and estradiol-induced TGF-b2 in
A549 cells.
Based on our current results, it can be presumed that the
biologically active form of TGF-b2 is generated in A549 cells
after stimulation with resveratrol. The mechanisms underlying
the conversion of the latent precursors to the biologically ac-
tive form of TGF-b are complex and are not yet fully under-
stood [8]. Further study is needed to determine how
resveratrol induces the active form of TGF-b in A549 cells.
In summary, we showed that endogenous TGF-b, which is
induced by resveratrol via estrogen receptors, activated
TGF-b/Smad signaling in an autocrine manner in A549 cells.
Thus, the eﬀects of resveratrol on TGF-b expression and sig-
naling might contribute, at least in part, to the beneﬁcial eﬀects
of this molecule.References
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